Insider Selling: Adaptimmune Therapeutics (NASDAQ:ADAP) Director Sells 4,828,206 Shares of Stock

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Director Ali Behbahani sold 4,828,206 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $0.01, for a total transaction of $48,282.06. Following the sale, the director owned 14,671,794 shares in the company, valued at $146,717.94. The trade was a 24.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ali Behbahani also recently made the following trade(s):

• On Monday, August 18th, Ali Behbahani sold 14,671,794 shares of Adaptimmune Therapeutics stock. The shares were sold at an average price of $0.01, for a total transaction of $146,717.94.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.0571 on Thursday. The stock has a market capitalization of $15.13 million, a price-to-earnings ratio of -0.09 and a beta of 2.18. The company has a fifty day moving average of $0.20 and a 200 day moving average of $0.30. Adaptimmune Therapeutics PLC has a fifty-two week low of $0.0520 and a fifty-two week high of $1.33. The company has a debt-to-equity ratio of 4.24, a quick ratio of 1.29 and a current ratio of 1.52.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $13.68 million during the quarter, compared to analysts’ expectations of $11.04 million. Adaptimmune Therapeutics had a negative net margin of 260.82% and a negative return on equity of 163.73%. As a group, sell-side analysts forecast that Adaptimmune Therapeutics PLC will post -0.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Mizuho cut shares of Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the company from $1.50 to $0.50 in a research note on Thursday, June 26th. Wall Street Zen assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday, May 16th. They set a “buy” rating for the company. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 14th. Guggenheim cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday, July 29th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics currently has a consensus rating of “Hold” and an average price target of $1.35.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in shares of Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after buying an additional 869,949 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after buying an additional 58,787 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Adaptimmune Therapeutics by 87.7% in the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after buying an additional 152,780 shares in the last quarter. Two Seas Capital LP bought a new stake in shares of Adaptimmune Therapeutics in the 4th quarter worth about $7,992,000. Finally, Long Focus Capital Management LLC lifted its holdings in shares of Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.